1. Home
  2. OXM vs OMER Comparison

OXM vs OMER Comparison

Compare OXM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Industries Inc.

OXM

Oxford Industries Inc.

HOLD

Current Price

$35.82

Market Cap

675.3M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.58

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXM
OMER
Founded
1942
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.3M
772.8M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
OXM
OMER
Price
$35.82
$10.58
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$38.00
$32.50
AVG Volume (30 Days)
579.1K
2.0M
Earning Date
06-10-2026
05-14-2026
Dividend Yield
6.80%
N/A
EPS Growth
N/A
98.15
EPS
1.00
0.62
Revenue
$1,477,834,000.00
$29,868,000.00
Revenue This Year
$2.85
N/A
Revenue Next Year
$2.63
$233.22
P/E Ratio
$38.14
$16.90
Revenue Growth
N/A
N/A
52 Week Low
$30.57
$2.95
52 Week High
$51.61
$17.65

Technical Indicators

Market Signals
Indicator
OXM
OMER
Relative Strength Index (RSI) 36.84 46.63
Support Level $33.84 $9.54
Resistance Level $41.58 $12.06
Average True Range (ATR) 2.57 0.81
MACD -0.54 0.18
Stochastic Oscillator 8.28 91.21

Price Performance

Historical Comparison
OXM
OMER

About OXM Oxford Industries Inc.

Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: